Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 11/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 14/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961155 | 0.89 | CHRNB2 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2952067 | 0.86 | CHRNB2 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2959703 | 0.84 | CHRNB2 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2958908 | 0.83 | CHRNB4 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2952778 | 0.83 | CHRNB2 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5996622 | 0.81 | CHRNB4 (0.58) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2952359 | 0.80 | CHRNB2 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2959693 | 0.77 | CHRNB2 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2961165 | 0.72 | CHRNB2 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2952658 | 0.72 | CHRNB2 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | disclosed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2001090109-A9 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNB4 38/4885CHRNA3 25/4885CHRNB2 17/4885 |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | CHRNB4 519/4885CHRNA3 387/4885CHRNB2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.